11 1 15 F H H t I P T Ti I i 1 I T n H Klaus Vedfelt Introduction Madrigal Pharmaceutical's (NASDAQ:MDGL) stock is essentially unchanged since my last look in June, when I expressed concern over GLP-1s, like Eli Lilly's (LLY) Zepbound, popping up in treatment guidelines for metabolic dysfunction-associated steatohepatitis (MASH), effectively limiting the market for Rezdiffra, the first drug indicated for MASH. Rezdiffra reported Q2 '24 earnings on Wednesday, the company's first quarter since its launch (via ...